Table 3.
Change in plasma lipid and lipoprotein concentrations between baseline and follow-up levels according to lipid peroxidation at admission.
| LPO ≤ 1948 μM a | LPO > 1948 μM a | ANCOVA Adjusted p-Value d |
|
|---|---|---|---|
| First follow-up b | |||
| TC, mg/dL | 186 [163–210] | 195 [157–215] | 0.763 |
| LDL-c, mg/dL | 123 [102–139] | 107 [102–135] | 0.475 |
| HDL-c, mg/dL | 58 [47–66] | 49 [36–67] | 0.392 |
| TG, mg/dL | 107 [83–139] | 115 [101–168] | 0.372 |
| TC/HDL-c | 3.4 [2.9–4.5] | 3.5 [2.8–5.2] | 0.306 |
| CRP, mg/L | 1.6 [1–4.3] | 1.7 [1–4.3] | 0.703 |
| Second follow-up c | |||
| TC, mg/dL | 192 [174–211] | 207 [197–230] | 0.026 |
| LDL-c, mg/dL | 114 [99–128] | 131 [120–147] | 0.025 |
| HDL-c, mg/dL | 57 [45–65] | 48 [38–62] | 0.031 |
| TG, mg/dL | 109 [86–127] | 127 [107–150] | 0.002 |
| TC/HDL-c | 3.4 [2.9–3.6] | 3.9 [3.4–4.8] | 0.003 |
| CRP, mg/L | 2.5 [1–5.25] | 5.8 [2–15] | 0.072 |
Abbreviations: CRP—C-reactive protein; HDL-c—high-density cholesterol; LDL-c—low-density cholesterol; LPO—lipid peroxidation; TC—total cholesterol; TC/HDL-c—total cholesterol/high-density cholesterol ratio; TG—triglycerides. Values are reported as median (IQR). Significant values (p < 0.05) are bold. a Previously estimated through the optimal operating point of LPO as described in ref. [10]. b Median follow-up time of the global COVID-19 survivors’ cohort was 79 [68–93] days, no differences were observed between groups (p > 0.05). c Median follow-up time of the global COVID-19 survivors cohort was 514 [427–617] days, no differences were observed between groups (p > 0.05). d When the Levene test was significant, we used log10-transform. The normality of residuals was verified.